THERAPY DOSSIER · th-60ed6f6135f1

BLF501, a synthetic C-glycoside ligand of sodium glucose cotransporter 1

Drug · No confident ChEMBL match; synthetic SGLT1 C-glycoside ligand (research)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; synthetic SGLT1 C-glycoside ligand (research)
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24495286 ↗2014Reported benefit

Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis.

MouseChemical/toxinBALB/c; SGLT-1 knockout on a C57BL/6 background; nude SKH-1 for the tumour studyFemalen = n=7 per group in the mucositis models, with n=14 split betw…Oral gavage in 100 microlitres of saline25 micrograms/kg, with 0.25 and 2.5 micrograms/kg also test…Administered at the same time as each chemotherapy injection

Model: Chemotherapy-induced gastrointestinal mucositis: single intraperitoneal doxorubicin 20 mg/kg, or intraperitoneal doxorubicin 7 mg/kg plus 5-fluorouracil 100 ng/kg once weekly for three weeks

BLF501 at 25 micrograms/kg preserved crypt proliferation (3.3 +/- 0.5 per cent versus 1.3 +/- 0.2 per cent at 48 hours), limited villus height loss (-12.31 +/- 1.58 per cent versus -36.15 +/- 2.56 per cent) and restored ZO-1, beta-catenin, caspase-3 and ERM expression; it had no effect in SGLT-1 kn…

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…